KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $2.1 billion.

  • Sarepta Therapeutics' Total Non-Current Liabilities fell 834.01% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 834.01%. This contributed to the annual value of $2.4 billion for FY2024, which is 88.26% up from last year.
  • Sarepta Therapeutics' Total Non-Current Liabilities amounted to $2.1 billion in Q3 2025, which was down 834.01% from $2.3 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Total Non-Current Liabilities registered a high of $2.7 billion during Q4 2022, and its lowest value of $2.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $2.3 billion (2025), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Sarepta Therapeutics' Total Non-Current Liabilities skyrocketed by 2509.52% in 2022, and later tumbled by 1417.79% in 2023.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Total Non-Current Liabilities stood at $2.2 billion in 2021, then grew by 24.36% to $2.7 billion in 2022, then fell by 12.54% to $2.4 billion in 2023, then increased by 0.88% to $2.4 billion in 2024, then decreased by 10.51% to $2.1 billion in 2025.
  • Its Total Non-Current Liabilities was $2.1 billion in Q3 2025, compared to $2.3 billion in Q2 2025 and $2.3 billion in Q1 2025.